Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...
BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
Surgery may be in your future, but a painful recovery doesn’t have to be. Physicians can help pave the way for a smooth recovery before a patient even gets to the hospital. The iovera° treatment is a ...
TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
In 2021, it was estimated that about 23% of adults living in Las Vegas, NV had arthritis. Osteoarthritis (OA), the most common form of arthritis, affects millions of people worldwide. OA symptoms can ...
Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
See “Non-GAAP Financial Information” below. “We entered 2025 sharply focused on our 5x30 strategy and our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback